WASHINGTON, May 22, 2018 /PRNewswire-USNewswire/ -- UsAgainstAlzheimer's Chairman George Vradenburgtoday issued the following statement regarding the termination of clinical trial testing of the Alzheimer's drug atabecestat by Janssen:
"To each individual who participated in the atabecestat study and to their families and caregivers also impacted
Thank you, Janssen, for your commitment to curing a disease that impacts almost 6 million people in the U.S. and more than 50 million worldwide. Your continued effort to find a cure amidst the growing number of drug failures and the rising costs of research and development gives hope to and shows compassion for the millions living with the disease and their hardworking caregivers. What we have learned through the atabecestat study, along with your future work, will accelerate progress towards treatments and a cure."
Connect with UsAgainstAlzheimer's.Learn about UsA2's work around the globe through our social channels:
https://twitter.com/UsAgainstAlz https://www.usagainstalzheimers.org/ https://www.facebook.com/UsAgainstAlz/
Founded in 2010, UsAgainstAlzheimer's (UsA2) is an innovative non-profit organization demanding – and delivering – a solution to Alzheimer's. Driven by the suffering of millions of families, UsAgainstAlzheimer's presses for greater urgency from government, industry and the scientific community in the quest for an Alzheimer's cure – accomplishing this through effective leadership, collaborative advocacy, and strategic investments.
Contact Melissa Green 202.429.4940 | firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/usagainstalzheimers-statement-on-alzheimers-drug-development-300652801.html
Subscribe to our Free Newsletters!